GLENMARK PHARMACEUTICALS LTD. - 532296 - Clarification On News Item
Clarification on media report titled as 'Glenmark in talks to sell up to 30% in API biz to PremjiInvest' published on economictimes.indiatimes.com dated 23rd August,201923-08-2019
23-08-2019
Glenmark Pharmaceuticals Ltd - 532296 - Clarification sought from Glenmark Pharmaceuticals Ltd
The Exchange has sought clarification from Glenmark Pharmaceuticals Ltd with respect to news article appearing on economictimes.indiatimes.com August 23, 2019, titled "Glenmark in talks to sell up to 30% in API biz to PremjiInvest".The reply is awaited.23-08-2019
GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark Pharmaceuticals receives ANDA approval for Fulvestrant Injection, 250 mg/5 mL (50 mg/mL)23-08-2019
GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark receives approval for combination of Remogliflozin Etabonate and Metformin Hydrochloride for adults with type 2 diabetes in India19-08-2019
Glenmark plans to divest non-core global assets to reduce debt by Rs 800 cr
Apart from rationalising costs, the company is also aiming to divest some of its non-core global assets as well as bring in a minority investor in to Glenmark Life Sciences14-08-2019
Glenmark Pharmaceuticals Ltd - 532296 - Unaudited Financial Results For The First Quarter Ended June 30,2019
Pursuant to Regulations 30 and 33 of the SEBI LODR, 2015, we wish to inform you that Board has today at its meeting approved the Unaudited Financial Results for the First Quarter ended June 30, 2019. The said meeting of the Board commenced at 2.00 p.m. and concluded at 6.30 p.m. The copy of the said results together with Management Discussion & Analysis, Press Release and Limited Review Report of the Auditors is enclosed herewith. These are also being made available on the website of the Company at www.glenmarkpharma.com. You are requested to take the same on record.13-08-2019
GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Enclosed please find herewith the details of Earnings Call slated for Wednesday, August 14, 2019 at 8:30 a.m. - 9:30 a.m. (IST), for your information and record. Please note that the recording of the call will be available on our website within 24 hours of the call.05-08-2019
Glenmark Pharmaceuticals Ltd - 532296 - Closure of Trading Window
We have to inform you that, pursuant to Regulation 29 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, a meeting of the Board of Directors will be held on Tuesday, August 13, 2019, inter alia, to consider and approve the Unaudited Financial Results of the Company for the First Quarter ended June 30, 2019. Further, as per the "Code of Conduct for Prevention of Insider Trading" and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 the Company has intimated its Directors and other designated persons regarding the closure of trading window from June 30, 2019 to August 15, 2019 (both days inclusive) for the purpose of approval of Unaudited Financial Results for the First Quarter ended June 30, 2019.31-07-2019
Glenmark Pharmaceuticals Ltd - 532296 - Closure of Trading Window
We have to inform you that, pursuant to Regulation 29 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, a meeting of the Board of Directors will be held on Tuesday, August 13, 2019, inter alia, to consider and approve the Unaudited Financial Results of the Company for the First Quarter ended June 30, 2019. Further, as per the "Code of Conduct for Prevention of Insider Trading" and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 the Company has intimated its Directors and other designated persons regarding the closure of trading window from June 30, 2019 to August 15, 2019 (both days inclusive) for the purpose of approval of Unaudited Financial Results for the First Quarter ended June 30, 2019.31-07-2019
Glenmark Pharmaceuticals Ltd - 532296 - Board Meeting Intimation for Considering And Approving Unaudited Financial Results Of The Company For The First Quarter Ended June 30, 2019
GLENMARK PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2019 ,inter alia, to consider and approve the Unaudited Financial Results of the Company for the First Quarter ended June 30, 2019. Further, as per the "Code of Conduct for Prevention of Insider Trading" and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 the Company has intimated its Directors and other designated persons regarding the closure of trading window from June 30, 2019 to August 15, 2019 (both days inclusive) for the purpose of approval of Unaudited Financial Results for the First Quarter ended June 30, 2019.31-07-2019